Beta test rollout. This site is in community QA — please send feature requests, bug reports and data corrections on the Feedback page or on GitHub.

Home
    Disclaimer
    ← Back to 5-MeO-DALT
    5-MeO-DALT molecular structure

    5-MeO-DALT Stats & Data

    Psychedelic Research-chemical
    Foxtrot 5meodalt
    PubChem CID 50878551
    PubChem
    MW270.37
    FormulaC17H22N2O
    LogP2.8
    IUPACN-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-prop-2-enylprop-2-en-1-amine
    InChIKeyHGRHWEAUHXYNNP-UHFFFAOYSA-N
    Chemical Class Substituted tryptamine
    Psychoactive Class Psychedelic
    Half-Life Unknown (subjective effects typically 2–4 h orally; smoked route peaks within minutes and resolves within ~45 min)

    Receptor Profile

    Receptor Actions

    Agonists
    5-HT1A receptor agonist (full)
    5-HT2A receptor agonist (full)
    5-HT2B receptor agonist
    5-HT2C receptor agonist
    Inhibitors
    Dopamine reuptake inhibitor
    Serotonin reuptake inhibitor

    Subjective Effects

    Physical

    The physical effects of 5-MeO-DALT can be broken down into several components which progressively intensify proportional to dosage.

    • Spontaneous tactile sensations: The body high of 5-MeO-DALT can be described as a motionless, constant, sharp and all-encompassing tingling sensation. This maintains a consistent presence that steadily rises with the come up and hits its limit once the peak has been reached.
    • Stimulation
    • Tactile enhancement
    • Temperature regulation loss
    • Increased heart rate
    • Pupil dilation
    Cognitive

    The head space of 5-MeO-DALT is described by many as one which is both insightful and relatively normal in its thought processes even at moderate to high doses.

    • Analysis enhancement
    • Thought acceleration
    • Time distortion
    • Novelty enhancement
    • Sexual arousal
    • Conceptual thinking
    • Thought connectivity
    • Current mind state enhancement
    • Personal bias suppression
    • Memory suppression
    • Ego death
    • Wakefulness
    Sensory
    Auditory
    • Enhancements
    • Distortions
    • Hallucinations
    Visual · Distortions

    5-MeO-DALT presents a full and complete array of possible visual distortions.

    • Drifting: (Melting, flowing, breathing and morphing) - In comparison to other psychedelics, this effect can be described as simplistic, slow and smooth in motion, static in appearance and unrealistic in style.
    • Tracers
    • Colour shifting
    • Symmetrical texture repetition
    Visual · Enhancements

    5-MeO-DALT presents a full and complete array of possible visual enhancements.

    • Acuity enhancement
    • Colour enhancement
    • Pattern recognition enhancement

    Forked from Subjective Effect Documentation by Josie Kins, September 2015. Via dose.wiki (CC0).

    Toxicity

    PsychonautWiki

    The toxicity and long-term health effects of recreational 5-MeO-DALT use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because 5-MeO-DALT is a research chemical with very little history of human usage. Anecdotal reports from those who have tried 5-MeO-DALT suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption. It is strongly recommended that one use harm reduction practices when using this substance.

    Effect Profile

    Curated + 38 Reports
    Psychedelic 8.8

    Strong visuals, headspace, auditory effects, and body load

    Visual Intensity×3
    1010
    Headspace Depth×3
    103.2
    Auditory Effects×1
    1010
    Body Load / Somatic Effects×1
    106.5
    Catalog Erowid
    Based on reports from:
    Effect Index Restless Mind — nervewing TiHKAL TiHKAL #56: 5-MeO-DALT Bluelight Big & Dandy Thread Erowid Experience Reports PsychonautWiki 5-MeO-DALT The Drug Users Bible 5-MeO-DALT

    Duration Timeline

    Bluelight
    Onset Comeup Peak Offset After Effects
    Oral
    10-15 minutes
    15-19 minutes
    1-1.5 hours
    1-2 hours
    Total: 3-6 hours
    Insufflated
    4-10 minutes
    10-15 minutes
    1-1.5 hours
    1-2 hours
    Smoked
    0 minutes
    0 minutes
    0-6 minutes
    6-12 minutes
    6-12 minutes
    Total: 15-20 minutes hours

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    Unknown (subjective effects typically 2–4 h orally; smoked route peaks within minutes and resolves within ~45 min)
    Addiction Potential
    Low; no evidence of physical dependence. Some users report psychological habituation with frequent use.

    Tolerance Decay

    Full tolerance 1d Half tolerance 7d Baseline ~14d

    Tolerance data are extrapolated from general psychedelic tolerance patterns; specific pharmacodynamic tolerance studies for 5-MeO-DALT are lacking. Users commonly report diminished effects with re-dosing on the same day and partial tolerance persisting for several days to a week.

    Cross-Tolerances

    Other tryptamines (e.g., DMT, 5-MeO-MiPT)
    Classical psychedelics (LSD, psilocin)

    Experience Report Analysis

    Erowid
    69 Reports
    38 Single-substance
    2004–2017 Date Range
    56 With Age Data
    22 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid

    Effects aggregated from 38 experience reports (38 single-substance Erowid)

    38 Reports
    22 Effects Detected
    10 Positive
    6 Adverse
    6 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.

    Positive Effects 10

    Visual Distortions 71.1% (95% interval 55 to 83 percent) 70%
    Stimulation 44.7% (95% interval 30 to 60 percent) 70%
    Music Enhancement 34.2% (95% interval 21 to 50 percent) 70%
    Color Enhancement 31.6% (95% interval 19 to 48 percent) 70%
    Euphoria 31.6% (95% interval 19 to 48 percent) 70%
    Empathy 26.3% (95% interval 15 to 42 percent) 70%
    Tactile Enhancement 18.4% (95% interval 9 to 33 percent) 70%
    Body High 15.8% (95% interval 7 to 30 percent) 70%
    Open-Eye Visuals 13.2% (95% interval 6 to 27 percent) 70%
    Closed-Eye Visuals 7.9% (95% interval 3 to 21 percent) 70%

    Adverse Effects 6

    Anxiety 36.8% (95% interval 23 to 53 percent) 70%
    Muscle Tension 31.6% (95% interval 19 to 48 percent) 70%
    Confusion 18.4% (95% interval 9 to 33 percent) 70%
    Nausea 13.2% (95% interval 6 to 27 percent) 70%
    Increased Heart Rate 10.5% (95% interval 4 to 24 percent) 70%
    Motor Impairment 7.9% (95% interval 3 to 21 percent) 70%

    Dose-Response Correlation

    How effect frequency changes across dose levels. Whiskers, and the numbers' hover text, give each figure's 95% interval.

    Not drawn, too few reports (a dose tier needs 20): Oral Heavy (n=10). Why 20?

    Dosage Distribution

    Dose distribution from experience reports, one dose per report (the first listed). Values above Q3 + 3×IQR are left out as outliers.

    Median: 40.0 mg IQR: 30.0–60.0 mg n=35 2 outliers left out

    Real-World Dose Distribution

    62K Doses

    From 80 individual dose entries. Values above Q3 + 3×IQR are left out as outliers.

    Oral (n=60)

    Median: 30.0mg 25th: 24.0mg 75th: 60.0mg 90th: 86.5mg

    Smoked (n=8)

    Median: 17.5mg 25th: 10.0mg 75th: 20.0mg 90th: 21.5mg

    Common Combinations

    Most co-occurring substances, as a share of all 69 reports filed under 5-MeO-DALT; whiskers are 95% intervals

    Form / Preparation

    Most common forms and preparations, as a share of the 55 reports that give one; whiskers are 95% intervals

    Body-Weight Dosing

    Dose per kg of body weight, one dose per report (the first listed), from reports giving a weight of 30–250 kg. Values above Q3 + 3×IQR are left out as outliers.

    Median: 0.588 mg/kg IQR: 0.456–0.945 mg/kg n=33 1 outlier left out

    Redose Patterns

    Redosing behavior across 58 reports

    19.0% (95% interval 11 to 31 percent) Redosed
    1.3 Avg Doses
    45m Median Interval
    Read full reports on Erowid →

    Legal Status

    Country Status Notes
    Austria Since January 1, 2012, 5-MeO-DALT is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).
    China As of October 2015 5-MeO-DALT is a controlled substance in China.
    Germany 5-MeO-DALT is controlled under the NpSG ( New Psychoactive Substances Act ) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person, placing it on the market and trading is punishable. Possession is illegal but not punishable. The legislator considers it possible that orders of 5-MeO-DALT are punishable as an incitement to place it on the market.
    Japan 5-MeO-DALT became a controlled substance in Japan from April 2007, by amendment to the Pharmaceutical Affairs Law.
    Singapore 5-MeO-DALT is listed in the Fifth Schedule of the Misuse of Drugs Act (MDA) and therefore illegal in Singapore as of May 2015.
    Slovakia 5-MeO-DALT is a Schedule I substance in Slovakia as of December 1, 2021
    Sweden Sveriges riksdag added 5-MeO-DALT to schedule I ("substances, plant materials and fungi which normally do not have medical use") as narcotics in Sweden as of May 1, 2012, published by Medical Products Agency in their regulation LVFS 2012:6 listed as 5-MeO-DALT N-allyl-N-2-(5-metoxi-1H-indol-3-yl)etyl-prop-2-en-1-amin.
    Switzerland 5-MeO-DALT is a controlled substance specifically named under Verzeichnis E.
    United Kingdom 5-MeO-DALT became a Class A drug in the UK on January 7, 2015 after an update to the tryptamine blanket ban.
    United States 5-MeO-DALT is not scheduled at the federal level in the United States, but it is likely that it could be considered an analog of 5-Meo-DiPT, which is a controlled substance in USA, or an analog of another tryptamine, in which case purchase, sale, or possession could be prosecuted under the Federal Analog Act.
    United States - Florida 5-MeO-DALT is a Schedule I controlled substance in the state of Florida, making it illegal to buy, sell, or possess.

    Harm Reduction

    drugs.wiki

    Potency is moderate by mass but inter-individual response is erratic; weigh doses on an accurate 0.001 g scale and titrate cautiously to avoid accidental high dosing. Rapid oral onset (often within 10–30 minutes) and a short peak make premature redosing tempting; wait at least 90 minutes after a first dose to assess the plateau. Insufflation is widely reported as irritating, with a bitter/chemical drip and unpredictable intensity; avoid large lines and consider oral use instead to reduce overdose risk. Vaporization/smoking produces an immediate, intense but brief peak; begin with 1–2 mg test puffs and use precise measurement or volumetric dosing to avoid overshooting. Combining with MAOIs significantly raises risk due to potentiation of tryptamines; avoid Syrian rue/ayahuasca or pharmaceutical MAOIs near 5-MeO-DALT sessions. As a serotonergic psychedelic, it can interact adversely with SSRIs/SNRIs, tramadol, DXM, lithium, and other serotonergics; these combinations increase serotonin toxicity risk. Some users report headaches, chest tightness, and vasoconstriction; maintain gentle hydration and avoid hot environments and stimulant combinations. A minority report dysphoria, confusion, derealization, or panic; use in a safe setting with a sober sitter if inexperienced, and avoid if you have a personal/family history of psychosis or bipolar disorder. Test your sample (reagents, and where available GC/MS or FTIR drug checking) to rule out mislabeling/adulterants; ‘research chemical’ markets are inconsistent. Effects appear to exhibit cross-tolerance with other psychedelics; spacing sessions by at least 1–2 weeks helps restore sensitivity and reduces psychological strain. Avoid driving or hazardous activities until fully baseline, as perception and coordination may be altered beyond the subjective ‘come-down.’

    References

    Data Sources

    Cited References

    Additional references

    ← Back to 5-MeO-DALT